Screening for diminished ovarian reserve in Portugal: a cost-saving answer to shorten the fertility journey

Author:

Xavier Pedro1,Dantas Sofia2,Almeida-Santos Teresa3,Soares Sérgio Reis4,Imhoff Ryan J5ORCID,Genovez Victória6,Modesto Cátia7,Gens Helena8,Correia Inês9,Catalão Carlos10

Affiliation:

1. President of the Portuguese Society of Reproductive Medicine (SPMR); Gynaecology-Obstetrics specialist, sub-speciality in Reproductive Medicine, Centre for Reproduction Genetics Prof. Alberto Barros, 4100-021, Portugal

2. Gynaecology-Obstetrics specialist, sub-speciality in Reproductive Medicine, Hospital Senhora da Oliveira, Guimarães, 4835-044, Portugal

3. Gynaecology-Obstetrics specialist, sub-speciality in Reproductive Medicine, Centro Hospitalar Universitário de Coimbra (CHUC), Coimbra, 3004-561, Portugal

4. Gynaecology-Obstetrics specialist, sub-speciality in Reproductive Medicine, IVI (Instituto Valenciano de Infertilidade), Lisbon, 1800-282, Portugal

5. Research Scientist II, CTI Clinical Trial & Consulting Services, Covington, KY 41011, USA

6. Market Access Associate II, CTI Clinical Trial & Consulting Services Portugal, Lisbon, 1072-274, Portugal

7. HTA & Market Access Associate II, CTI Clinical Trial & Consulting Services Portugal, Lisbon, 1070-274, Portugal

8. Medical Affairs Lead, Roche Sistemas de Diagnósticos, Amadora, 2720-413, Portugal

9. Medical Science Liaison, Roche Sistemas de Diagnósticos, Amadora, 2720-413, Portugal

10. Access & Innovation Director, Roche Sistemas de Diagnósticos, Amadora, 2720-413, Portugal

Abstract

Aim: Assess the budget impact of nationwide screening for diminished ovarian reserve (OR), via anti-Müllerian hormone (AMH) levels, to the Portugal National Health System (NHS). Patients & methods: The clinical journey was determined using literature and the family planning decision-making process/response using survey results. A panel of four local clinicians validated all assumptions/inputs. Results: Screening for OR led to an expected savings of € 9.4 million for the NHS, driven by a 24% reduction in medically assisted reproduction (MAR) use. When needed, referral for MAR was earlier and more women used first-line versus second-line techniques. The model estimated a 12% decrease in failure. Conclusion: This model shows AMH screening may allow more informed decisions, leading to a shorter fertility journey, more efficient use of treatments, and substantial cost-savings for the NHS.

Publisher

Becaris Publishing Limited

Subject

Health Policy

Reference38 articles.

1. Pordata. Idade média da mãe ao nascimento do primeiro filho. INE - Indicadores Demográficos Fontes de Dados. www.pordata.pt/portugal/idade+media+da+mae+ao+nascimento+do+primeiro+filho-805 (2020).

2. Birth rate by country - Thematic Map - Europe. https://www.indexmundi.com/map/?v=25&r=eu&l=en (2020).

3. Pordata. Saldos populacionais anuais: total natural e migratório. INE - Estatísticas de Nados-Vivos; INE - Estimativas Anuais da População Residente; INE - Estatísticas de Óbitos Fontes de Dados. www.pordata.pt/portugal/saldos+populacionais+anuais+saldo+total++saldo+natural+e+saldo+migratorio-657 (2020).

4. Conselho Nacional De Procriação Medicamente Assistida (CNPMA). Relatório - Atividade Desenvolvida pelos Centros de PMA em 2017. www.cnpma.org.pt/cnpma/Paginas/Relatorios-da-Atividade-em-pma.aspx (2021).

5. ESHRE. Factsheet on ART. www.eshre.eu/Europe/Factsheets-and-infographics (2020).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3